 |
Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2010 Financial Results
Jul 14, 2010
|
20.0 KB |
|
| |
TUSTIN, CA, Jul 14, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the fourth quarter and fiscal year (FY) 2010 ended April 3...
|
|
Peregrine Initiates Second Randomized Phase IIb Lung Cancer Trial Using First-In-Class PS-Targeting Monoclonal Antibody Bavituximab
Jul 14, 2010
|
12.2 KB |
|
| |
TUSTIN, CA, Jul 14, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a second randomized Phase IIb non-small cell lung cancer (...
|
|
Peregrine to Report Fourth Quarter and Fiscal Year 2010 Financial Results After Market on July 14, 2010
Jun 30, 2010
|
7.7 KB |
|
| |
TUSTIN, CA, Jun 30, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the fourth quarter and fiscal year 201...
|
|
Peregrine Pharmaceuticals Joins Russell 3000 Index
Jun 28, 2010
|
8.3 KB |
|
| |
TUSTIN, CA, Jun 28, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that on June 25, 2010 it was added to the Russell 3000(R) Index following the Ru...
|
|
Peregrine Provides Update on Government-Sponsored Research Program
Jun 28, 2010
|
10.1 KB |
|
| |
TUSTIN, CA, Jun 28, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update on its government-sponsored research programs. Under its first governme...
|
|
Peregrine Set to Join Russell 3000
Jun 14, 2010
|
8.8 KB |
|
| |
TUSTIN, CA, Jun 14, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, is set to join the broad-market Russell 3000(R) Index when Russell Investments reconstitutes its...
|
|
Peregrine to Highlight Key Clinical Data From Four ASCO Presentations at Needham Healthcare Conference
Jun 9, 2010
|
13.3 KB |
|
| |
TUSTIN, CA, Jun 09, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today will present tumor response and progression-free survival data from three clinical Phase II tr...
|
|
Positive Phase II Lung Cancer Data to Be Presented at ASCO Support Recently Opened Registrational Phase IIb Trial for Bavituximab
Jun 4, 2010
|
12.3 KB |
|
| |
TUSTIN, CA, Jun 04, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced positive data from a Phase II clinical trial treating front-line non-small cell lung...
|
|
Glioblastoma Multiforme Data From Peregrine's Novel Brain Cancer Therapy Cotara(R) to Be Reported at ASCO
Jun 3, 2010
|
13.0 KB |
|
| |
TUSTIN, CA, Jun 03, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced data to be presented on June 6, 2010 at the ASCO Annual Meeting from a Phase I trial...
|
|
Peregrine Pharmaceuticals to Present at the Needham & Company Ninth Annual Healthcare Conference
Jun 2, 2010
|
6.8 KB |
|
| |
TUSTIN, CA, Jun 02, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at Needham & Company's Ninth Annual Healthcare Conference on Wednesd...
|
|
New Progression-Free Survival Data From Peregrine's Bavituximab in Phase II Refractory Breast Cancer Trial to Be Presented at ASCO
May 28, 2010
|
11.9 KB |
|
| |
TUSTIN, CA, May 28, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced new median progression-free survival (PFS) data of 7.4 months from a Phase II trial ...
|
|
Phase II Advanced Breast Cancer Data to Be Presented at ASCO Highlight Promising Tumor Response and Progression-Free Survival Data With Peregrine's Bavituximab
May 27, 2010
|
11.7 KB |
|
| |
TUSTIN, CA, May 27, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced positive objective tumor response and median progression-free survival (PFS) data fr...
|
|
Peregrine to Present Lung, Advanced Breast, and Brain Cancer Clinical Data at 2010 ASCO Annual Meeting
May 20, 2010
|
11.6 KB |
|
| |
TUSTIN, CA, May 20, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that it will present cancer data from four clinical trials, including its first-in-class phosphatidylserine (PS)-targeting monoclonal antibody bavituximab and novel brain cancer therapy Cotara, at the 2010 ASCO Annual Meet...
|
|
Peregrine Pharmaceuticals to Present at the Rodman & Renshaw Sixth Annual Global Investment Conference
May 10, 2010
|
7.7 KB |
|
| |
TUSTIN, CA, May 10, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the Rodman & Renshaw Sixth Annual Global Investment Conference in...
|
|
Avid Bioservices to Highlight Integrated Commercial Manufacturing Capabilities at 2010 BIO International Convention
May 3, 2010
|
7.4 KB |
|
| |
TUSTIN, CA and CHICAGO, IL, May 03, 2010 (MARKETWIRE via COMTEX News Network) -- Avid Bioservices, Inc., a leading provider of integrated commercial manufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced its participation in the 2010 BIO International Convention.
-- Tuesday, May 4 through T...
|
|
Peregrine and Stason Enter Into Agreement for Innovative Tumor Necrosis Therapy (TNT) Technologies
May 3, 2010
|
13.5 KB |
|
| |
TUSTIN, CA and IRVINE, CA, May 03, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, and Stason Pharmaceuticals, a privately-held U.S.-based pharmaceutical company commer...
|
|
Three Presentations at AACR Annual Meeting Show Breadth of Applications for Peregrine's Innovative Phospholipid-Targeting Technologies
Apr 21, 2010
|
14.9 KB |
|
| |
WASHINGTON, DC and TUSTIN, CA, Apr 21, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced three data presentations at the AACR 101st Annual Meeting 2010 de...
|
|
New Preclinical Breast Cancer Study Shows Peregrine's PS-Targeting Antibodies Can Reverse Tumor-Induced Immune Suppression
Apr 19, 2010
|
12.4 KB |
|
| |
WASHINGTON, D.C. and TUSTIN, CA, Apr 19, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today reported data from a new preclinical study demonstrating that the company...
|
|
New Study Shows Combining Peregrine's Bavituximab With an Apoptosis-Inducing Agent Can Eradicate Tumors in a Model of Advanced Breast Cancer
Apr 15, 2010
|
11.5 KB |
|
| |
TUSTIN, CA, Apr 15, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the publication of new data highlighting the tumor-killing potential of its lead phosphatidylserine (PS)-targeting antibody bavituximab in combination with an agent that induces apoptosis, or programmed cell death. In this...
|
|
Peregrine Announces Data From Four Clinical Studies Will Be Presented at 2010 ASCO Annual Meeting
Apr 13, 2010
|
7.9 KB |
|
| |
TUSTIN, CA, Apr 13, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical stage biopharmaceutical company developing novel monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four clinical studies of bavituximab and Cotara(R) have been accepted for ...
|
|
|
= add release to Briefcase |
NASDAQ:PPHM
$1.62
- 0.05
|
Jul 30, 2010
4:00 PM ET |
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
To sign up for electronic delivery of shareholder materials click here
|
|
News Releases 
